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An intact B-box 2 domain is essential for the antiretroviral activity of TRIM5. We modeled the structure
of the B-box 2 domain of TRIM5 based on the existing three-dimensional structure of the B-box 2 domain of
human TRIM29. Using this model, we altered the residues predicted to be exposed on the surface of this
globular structure. Most of the alanine substitutions in these residues exerted little effect on the antiretroviral
activity of human TRIM5hu or rhesus monkey TRIM5rh. However, alteration of arginine 119 of TRIM5hu
or the corresponding arginine 121 of TRIM5rh diminished the abilities of the proteins to restrict retroviral
infection without affecting trimerization or recognition of the viral capsid. The abilities of these functionally
defective TRIM5 proteins to accelerate the uncoating of the targeted retroviral capsid were abolished.
Removal of the positively charged side chain from B-box 2 arginines 119/120/121 resulted in diminished
proteasome-independent turnover of TRIM5 and the related restriction factor TRIMCyp. However, testing of
an array of mutants revealed that the rapid turnover and retroviral restriction functions of this B-box 2 region
are separable.
Proteins of the tripartite motif (TRIM) family contain
RING, B-box, and coiled-coil domains and thus have also been
referred to as RBCC proteins (25). TRIM proteins often self-
associate and form aggregates called nuclear or cytoplasmic
bodies (3, 25, 27). Although TRIM proteins have been impli-
cated in transcriptional regulation, cell division, retroviral re-
striction, determination of cell polarity, and differentiation, the
precise functions of most TRIM proteins remain to be deter-
mined (15, 19, 34).
TRIM5 was identified in a random genetic screen as the
factor responsible for the early postentry block to human im-
munodeficiency virus type 1 (HIV-1) in Old World monkeys
(30). TRIM5 is a cytoplasmic protein that is capable of re-
stricting infection by different retroviruses in a species-depen-
dent manner (13, 29). Variation among TRIM5 proteins in
different primates accounts for the early postentry blocks to
infection by particular retroviruses (5, 9, 12, 13, 37). For ex-
ample, the TRIM5 proteins of several Old World monkey
species block HIV-1 infection (8, 13, 18), whereas the TRIM5
proteins of New World monkeys block infection by simian
immunodeficiency virus (29). TRIM5 from humans (TRIM5hu) is
not as potent in restricting HIV-1 infection as Old World
monkey TRIM5 proteins, but TRIM5hu potently restricts
other retroviruses, e.g., N-tropic murine leukemia virus (N-
MLV), equine infectious anemia virus (EIAV), and feline im-
munodeficiency virus (FIV) (8, 13, 21, 26, 37).
Variation in splicing of the TRIM5 primary transcript leads
to the expression of TRIM5 isoforms, designated , , and 
(25). The TRIM5 isoform contains, in addition to the RING,
B-box 2, and coiled-coil domains, a carboxy-terminal B30.2
(SPRY) domain. The B30.2(SPRY) domain is essential for the
antiretroviral activity of TRIM5 (32). In some cases, the dif-
ferences in the abilities of TRIM5 proteins from various
primate species to restrict particular retroviruses are deter-
mined by sequences in the B30.2(SPRY) domain (20, 22,
28, 35). The B30.2 domain of rhesus monkey TRIM5
(TRIM5rh) is required for specific recognition of the HIV-1
capsid (31). HIV-1 capsid recognition is also dependent on
TRIM5rh trimerization, which is mediated by the coiled-coil
and adjacent linker 2 regions (4, 12, 16).
Disruption of the TRIM5rh or TRIM5hu B-box 2 domain
by mutagenesis resulted in loss of retroviral restriction (11, 22,
24). Thus, it has been suggested that the B-box 2 TRIM5
mutants may lack an “effector” function important for restric-
tion. Studies following the fate of the HIV-1 and N-MLV
capsids in the cytoplasm of cells expressing TRIM5rh or
TRIM5hu, respectively, indicate that the conversion of par-
ticulate capsids to soluble capsid proteins is accelerated by a
restricting TRIM5 protein (24, 31). Thus, the B-box 2 domain
may contribute to this process.
In this work, we modeled the structure of the B-box 2 do-
mains of TRIM5rh and TRIM5hu based on the available
B-box 2 domain structure from the TRIM29 protein (9). The
modeled TRIM5 structure revealed that the B-box 2 domain is
globular and highly charged on its surface. We tested the
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hypothesis that residues predicted to be on the surface of the
B-box 2 domain contribute to the “effector” function of
TRIM5. These residues were individually altered, and the
phenotypes of the mutants were characterized. We found that
the positively charged arginine 121 residue on the surface of
the B-box 2 domain of TRIM5rh was important for the re-
striction of several retroviruses, including HIV, EIAV, and
FIV. Moreover, the homologous residue, arginine 119, of
TRIM5hu was found to be essential for the restriction of
N-MLV, EIAV, and FIV. Studies of the oligomerization, cap-
sid-binding abilities, and effects of these mutant proteins on
the infecting retroviral capsid suggested that this B-box 2 res-
idue contributes to the ability of TRIM5 to accelerate the
conversion of the particulate cytosolic capsid to soluble capsid
proteins. The analysis of a larger panel of mutants involving
residue 121 of TRIM5rh or residue 119 of TRIM5hu re-
vealed that changing the positively charged side chain of this
B-box 2 residue dramatically reduced TRIM5 turnover. The
B-box 2-dependent turnover of TRIM5 was not inhibited by
proteasome inhibitors. Some B-box 2 mutants of TRIM5rh
and TRIM5hu were long-lived but exhibited potent antiret-
roviral activity. Thus, the rapid turnover and effector functions
of this TRIM5 B-box 2 region are separable.
MATERIALS AND METHODS
Modeling the TRIM5 B-box 2 domain. The structure of the human TRIM5
B-box 2 domain and the immediate flanking regions was modeled using the
MODELLER (version 9.0) program (5) in Discovery Studio 1.7 (Accelrys Soft-
ware, Inc., San Diego, CA). The structure of the TRIM29 B-Box 2 domain
(Protein Data Bank file 2CSV) was used as the template for homology-based
protein modeling (9). The B-box protein sequences from human TRIM5 and
TRIM29 exhibit 50% sequence identity, and the TRIM5 model was built based
on the sequence alignment. The model was further refined through loop and side
chain refinement and energy minimization. The coordinates of zinc atoms were
derived from the template.
Creation of cells stably expressing TRIM5 variants. Retroviral vectors en-
coding wild-type or mutant TRIM5hu, TRIM5rh, or TRIMCyp proteins were
created using the pLPCX vector. Recombinant viruses were produced in 293T
cells by cotransfecting the pLPCX plasmids with the pVPack-GP and pVPack-
VSV-G packaging plasmids (Stratagene). The pVPack-VSV-G plasmid encodes
the vesicular stomatitis virus (VSV) G envelope glycoprotein, which allows effi-
cient entry into a wide range of vertebrate cells. Cf2Th canine thymocytes were
transduced and selected in 5 g/ml puromycin (Sigma).
Infection with viruses expressing GFP. Recombinant HIV-1, N-MLV, and
B-tropic murine leukemia virus (B-MLV) expressing green fluorescent protein
(GFP) were prepared as described previously (19). For infections, 3 104 Cf2Th
cells seeded in 24-well plates were incubated with virus for 24 h. The cells were
washed and returned to culture for 48 h and then subjected to fluorescence-
activated cell sorter analysis with a FACScan (Becton Dickinson). The FIV
vector expressing GFP was obtained from System Biosciences (Mountain View,
CA) and was prepared following the manufacturer’s instructions. The EIAV
vector expressing GFP was a gift from John Olsen (21). HIV-1, N-MLV, B-MLV,
FIV, and EIAV viral stocks were titrated by serial dilution on Cf2Th cells to
determine the concentrations of infectious viruses.
Protein analysis. Cellular proteins were extracted with radioimmunoprecipi-
tation assay buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1% sodium deoxycholate,
0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 2 mg/ml aprotinin, 2 mg/ml
leupeptin, 1 mg/ml pepstatin A, 100 mg/ml phenylmethylsulfonyl fluoride). The
cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE)
(10% acrylamide), followed by blotting them onto nitrocellulose membranes
(Amersham Pharmacia Biotech). The detection of protein by Western blotting
utilized monoclonal antibodies directed against the hemagglutinin (HA) epitope
FIG. 1. Modeling the B-box 2 domain of TRIM5hu based on the TRIM29 B-box 2 structure. Modeling of the TRIM5hu B-box 2 domain and
flanking sequences was performed using the Modeler program (Accelrys Software, Inc.). Modeling was based on the TRIM29 B-box 2 structure
(9). The C trace of the modeled TRIM5hu B-box 2 domain is shown, with the side chains of lysine 111 and arginine 119. The beginnings of the
L1 linker and the coiled coil are depicted in cyan and purple, respectively. The molecule is seen from the perspective of the putative trimer axis.
The globular B-box 2 domain is colored green, with basic and acidic residues shown in blue and red, respectively. The alignment of the B-box 2
domains of TRIM5rh and TRIM5hu with human TRIM29 (TRIM29hu) is shown below. Identical residues are highlighted in yellow. Residues
involved in coordinating zinc ions are colored red. Lysines 111/113 and arginines 119/121 of TRIM5hu and TRIM5rh, respectively, are colored
blue.
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tags (Roche) and monoclonal antibodies to -actin (Sigma). Detection of pro-
teins was performed by enhanced chemiluminescence (NEN Life Sciences Prod-
ucts), using anti-mouse immunoglobulin (for -actin) and anti-rat immunoglob-
ulin (for HA) secondary antibodies (Amersham Pharmacia Biotech).
TRIM5 turnover. The turnover rates of wild-type and mutant TRIM5
proteins were estimated as previously described (3). Briefly, cells expressing the
TRIM5 proteins were incubated with medium containing 100 g/ml cyclohexi-
mide, and the steady-state levels of TRIM5 protein were determined by Western
blotting cell lysates for the HA epitope tags or, as a control, for -actin, as
described above. In some cases, TRIM5 proteins with HA epitope tags at both
the N and C termini were studied. In some of the experiments, cycloheximide-
treated cells were also incubated with the proteasome inhibitor MG115 (50 M),
MG132 (50 M), or clasto-lactacystin (10 M) before lysis and Western blotting
as described above.
Localization of wild-type and mutant TRIM5 proteins. The localization of
TRIM5rh, TRIM5hu, or TRIMCyp variants in expressing cells was investi-
gated as previously described (2). Briefly, cells were grown overnight on 12-mm-
diameter coverslips and fixed in 3.9% paraformaldehyde (Sigma) in phosphate-
buffered saline (PBS) (Cellgro) for 30 min. The cells were washed in PBS,
incubated in 0.1 M glycine (Sigma) for 10 min, washed in PBS, and permeabilized
with 0.05% saponin (Sigma) for 30 min. Samples were blocked with 10% donkey
serum (Dako, Carpinteria, CA) for 30 min and incubated for 1 h with antibodies.
The anti-HA fluorescein isothiocyanate-conjugated 3F10 antibody (Roche) was
used to stain HA-tagged proteins. Subsequently, samples were mounted for
fluorescence microscopy by using the ProLong Antifade Kit (Molecular Probes,
Eugene, OR). Images were obtained with a Bio-Rad Radiance 2000 laser scan-
ning confocal microscope with Nikon 60 1.4 numerical aperture optics.
TRIM5 oligomerization. Approximately 1  107 293T cells transfected with
5 g of plasmids expressing TRIM5rh or TRIM5hu variants were lysed in
immunoprecipitation buffer and cross-linked with different concentrations (0 to
10 mM) of glycolbis-succinimidylsuccinate for 30 min as previously described
(11). The cross-linking reaction was stopped by adding 10 l of 1 M Tris-HCl.
After the cross-linking, samples were resuspended in 2 sample buffer and
incubated at 37°C for 30 min. The samples were analyzed by SDS-PAGE and
Western blotting with an anti-HA antibody (Roche).
HIV CA-NC expression and purification. HIV-1 CA-NC protein was ex-
pressed, purified, and assembled as previously described (6, 7). The pET11a
expression vector (Novagen) expressing the CA-NC protein of HIV-1 was used
to transform Escherichia coli BL-21(DE3). CA-NC expression was induced with
1 mM IPTG (isopropyl--D-thiogalactopyranoside) when the culture reached an
optical density of 0.6 at 600 nm. After 4 h of induction, the cells were harvested
and resuspended in 20 mM Tris-HCl (pH 7.5), 1 M ZnCl2, 10 mM 2-mercap-
toethanol, and protease inhibitors (Roche). Lysis was performed through soni-
cation, and the debris was pelleted for 30 min at 35,000  g. Nucleic acids were
stripped from the solution by using 0.11 equivalent of 2 M (NH4)2SO4 and the
same volume of 10% polyethylenimine. Nucleic acids were removed by stirring
and centrifugation at 29,500  g for 15 min. The protein was recovered by the
addition of 0.35 equivalent of saturated (NH4)2SO4. The protein was centrifuged
at 9,820  g for 15 min and resuspended in 100 mM NaCl, 20 mM Tris-HCl (pH
7.5), 1 M ZnCl2, and 10 mM 2-mercaptoethanol. The protein was dialyzed
against 50 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 M ZnCl2, and 10 mM
2-mercaptoethanol.
In vitro assembly of CA-NC complexes. HIV-1 CA-NC particles were assem-
bled in vitro by diluting the CA-NC protein to a concentration of 0.3 mM in 50
mM Tris-HCl (pH 8.0), 0.5 M NaCl, and 2 mg/ml DNA oligo-(TG)50. The
mixture was incubated at 4°C overnight and centrifuged at 8,600  g for 5 min.
The pellet was resuspended in assembly buffer (50 mM Tris-HCl [pH 8.0], 0.5 M
NaCl) at a final protein concentration of 0.15 mM (6, 7).
Binding of TRIM5rh variants to HIV-1 capsid complexes. 293T cells were
transfected with plasmids expressing wild-type or mutant TRIM5rh proteins.
Forty-eight hours after transfection, cell lysates were prepared as follows. Pre-
viously washed cells were resuspended in hypotonic lysis buffer (10 mM Tris, pH
7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol). The cell suspension was
frozen and thawed and incubated on ice for 10 min. Afterwards, the lysate was
centrifuged at full speed in a refrigerated Eppendorf microcentrifuge
(14,000  g) for 5 min. The supernatant was supplemented with 1/10 volume
of 10 PBS and then used in the binding assay. To test binding, 5 l of CA-NC
particles assembled in vitro was incubated with 200 l of cell lysate at room
temperature for 1 h. A fraction of this mixture was stored. The mixture was spun
through a 70% sucrose cushion (70% sucrose, 1 PBS, and 0.5 mM dithiothre-
itol) at 100,000  g in an SW55 rotor (Beckman) for 1 h at 4°C. After centrif-
ugation, the supernatant was carefully removed and the pellet was resuspended
in 1 SDS-PAGE loading buffer. The level of TRIM5rh proteins was deter-
mined by Western blotting, as described above.
RESULTS
Modeling the B-box 2 domain of human and rhesus
TRIM5 proteins. The B-box domains of TRIM proteins con-
tain conserved cysteine and histidine residues that have been
shown in some instances to bind zinc atoms (1). Modification
of particular cysteine residues predicted to bind zinc atoms in
the B-box 2 domain of TRIM5rh abrogates its anti-HIV-1
activity (11). To gain additional insights into the structure-
function relationships of TRIM5, we used the available struc-
ture of the B-box 2 domain of human TRIM29 to model this
domain of TRIM5 (Fig. 1). Both human and rhesus monkey
TRIM5 B-box 2 domains exhibit approximately 50% identity
to the B-box 2 domain of human TRIM29, implying a high
likelihood that the TRIM5 and TRIM29 B-box 2 domains are
folded similarly (Fig. 1). The modeled B-box 2 domain of
TRIM5 exhibits a globular structure, with the N-terminal
linker (L1) that connects the B-box 2 domain to the RING
domain and the C-terminal helical coiled coil projecting or-
thogonally from this globular structure (Fig. 1). The amphi-
pathic character of the nascent coiled-coil helix suggests a
probable orientation of the modeled B-box 2 domain with
respect to the trimer axis. The globular B-box 2 domain pre-
sents a polar surface with prominent clusters of positively and
negatively charged amino acids.
The role in antiretroviral activity of TRIM5 residues pre-
dicted to be on the B-box 2 surface. To understand the contri-
bution of the predicted surface-exposed residues of the B-box
2 domain to the anti-HIV-1 activities of TRIM5 proteins, we
changed these residues in the TRIM5rh B-box 2 domain in-
dividually to alanine (Fig. 2A). Dog cells (Cf2Th) stably ex-
pressing the different mutants (Fig. 2B) were challenged with
different amounts of recombinant HIV-1 expressing (HIV-1–
GFP) (Fig. 2C and D). Deletion of the B-box 2 domain of
TRIM5rh [	(97-129)] completely eliminated its ability to re-
strict HIV-1 (Fig. 2C and D). By contrast, all of the TRIM5rh
proteins with single amino acid changes restricted HIV-1 in-
fection. However, the K113A and R121A TRIM5rh mutants
inhibited HIV-1 infection less efficiently than the wild-type
TRIM5rh protein (Fig. 2C and D). Thus, replacement of
FIG. 2. TRIM5rh and TRIM5hu mutants and retroviral restriction. (A) The primary sequences of the B-box 2 domains from TRIM5rh and
TRIM5hu are aligned. Residues depicted in red are predicted to be exposed on the surface of the B-box 2 domain. The asterisks indicate residues
that were changed by site-directed mutagenesis. wt, wild type. (B) Cf2Th cells were transduced with the LPCX vector expressing HA-tagged
wild-type and mutant TRIM5rh proteins. Stable cell lines were selected with 5 g/ml of puromycin. Cell lysates were analyzed by Western blotting
using antibodies against HA (Anti-HA) and -actin. (C and D) Cf2Th cells expressing the indicated wild-type and mutant TRIM5rh proteins were
incubated with HIV-1–GFP, and GFP-positive cells were measured by fluorescence-activated cell sorting. The results of two independent
experiments were similar, and the results of one experiment are shown.
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individual TRIM5rh residues predicted to be exposed on the
surface of the B-box 2 domain with alanine exerted at most a
modest effect on anti-HIV-1 activity.
Lysine 113 and arginine 121 are predicted to be located on
opposite sides of the upper surface of the TRIM5rh B-box 2
domain (Fig. 1). To examine further the potential functional
roles of these basic residues, we altered lysine 113 and arginine
121 simultaneously to alanine residues. The K113A/R121A
TRIM5rh protein was expressed at a level equivalent to that
of the wild-type TRIM5rh protein (Fig. 3A). The susceptibil-
ity of Cf2Th cells expressing the K113A/R121A mutant to
infection by HIV-1, EIAV, and FIV was examined (Fig. 3B, C,
and D). For comparison, the abilities of these three retrovi-
ruses to infect cells expressing wild-type TRIM5rh or
TRIM5rh mutants with other alterations affecting the B-box 2
domain were examined in parallel. Cells expressing wild-type
TRIM5rh and the K103A mutant strongly resisted infection
by HIV-1, EIAV, and FIV. As expected, TRIM5rh variants
with deletions [	(1-132) and 	(97-129)] or disruption (C97A/
H100A) of the B-box 2 domain did not inhibit infection by the
three retroviruses. The antiretroviral activity of the K113A/
R121A mutant was significantly attenuated, similar to that of
the TRIM5rh 	(1-93) mutant, which lacks the RING and L1
regions. Thus, lysine 113 and arginine 121 contribute to the
antiretroviral activity of TRIM5rh.
Residues 113 and 121 of TRIM5rh were altered individu-
ally or in combination to other basic residues or to acidic
residues. The substitution of negatively charged residues for
arginine 121 completely eliminated the ability of TRIM5rh to
restrict HIV-1, EIAV, and FIV infections (Fig. 4A to D),
despite efficient expression of these mutants (see below). Sub-
stitution of acidic residues at position 113 exerted only modest
effects on the antiretroviral activity of TRIM5rh. The simul-
taneous replacement of lysine 113 with arginine and arginine
121 with lysine only minimally affected the ability of TRIM5rh
to inhibit HIV-1, EIAV, and FIV infection (see K113R/R121K
in Fig. 4A to C). Thus, the presence of a negatively charged
residue at position 121 is particularly disruptive of the antiret-
roviral activity of TRIM5rh.
Roles of charged B-box 2 surface residues in the antiretro-
viral activity of human TRIM5. Arginine 121 is conserved in
all primate TRIM5 proteins, whereas lysine 113 is conserved
in Old World primate TRIM5 proteins (see below). To ex-
amine the contributions of these basic residues to the antiret-
roviral function of another TRIM5 protein, the equivalent
residues, lysine 111 and arginine 119, of TRIM5hu were al-
tered. The abilities of the wild-type and mutant TRIM5hu
proteins to restrict infection of Cf2Th cells by N-MLV, EIAV,
and FIV were examined. Alteration of arginine 119 of
TRIM5hu to alanine resulted in complete loss of the ability to
restrict N-MLV and EIAV (Fig. 5A and C) and significant
reduction in activity against FIV (Fig. 5D). Alanine substitu-
tion for lysine 111 in TRIM5hu exerted less of an effect on
N-MLV and EIAV inhibition (Fig. 5A and C). The TRIM5hu
K111A mutant exhibited partial restricting activity against FIV
(Fig. 5D). As expected, none of the TRIM5hu variants were
active against B-MLV infection (Fig. 5B). Thus, the alteration
of arginine 119 significantly affects the retrovirus-restricting
ability of TRIM5hu.
To examine the role of charge in modulating the function of
arginine 119 of TRIM5hu, mutants were created with a basic
substitution (R119K) or acidic substitutions (R119E and
R119D) at this residue. The R119K mutant exhibited wild-type
levels of activity against N-MLV, EIAV, and FIV infections
(Fig. 6A to D). By contrast, the R119E and R119D mutants
were devoid of detectable antiretroviral activity. The antiret-
roviral activities of the R119E and R119D mutants were no
better than that of the C95A mutant, which has a disruption of
the B-box 2 domain. Apparently, as was seen for TRIM5rh,
introduction of an acidic residue at this position in TRIM5hu
abolishes antiretroviral activity.
Trimerization and capsid binding of TRIM5 B-box 2 mu-
tants. To investigate the mechanistic basis of the attenuation of
antiretroviral activity associated with changes in the B-box 2
residues, the mutants were compared with wild-type TRIM5
proteins for oligomerization and capsid-binding abilities. Both
TRIM5rh and TRIM5hu form trimers (16). Cross-linking of
lysates from cells expressing wild-type or mutant TRIM5 pro-
teins suggested that all of the human and rhesus monkey
TRIM5 mutants efficiently formed trimers (Fig. 7A and B
and data not shown). These data are consistent with previous
results demonstrating that the TRIM5 B-box 2 domain is not
necessary for trimerization (12).
The abilities of the TRIM5rh mutants to bind HIV-1
CA-NC complexes assembled in vitro were examined. As
shown in Fig. 8, deletion or amino acid alteration of the B-box
2 domain did not significantly compromise the ability of
TRIM5rh to bind HIV-1 capsid complexes. As expected (12,
31), deletion of the TRIM5rh coiled coil [	(132-233)] dis-
rupted its capsid-binding ability. Also as expected (14c, 31),
TRIM5hu associated less efficiently with HIV-1 capsid com-
plexes than TRIM5rh.
These results suggest that the changes introduced into the
TRIM5rh B-box 2 domain allow trimerization and HIV-1
capsid binding.
Effects of B-box 2 changes in TRIM5 on the fate of the
retroviral capsid in infected cells. Previous studies (24, 31)
suggested that restriction of HIV-1 and N-MLV infection is
accompanied by an accelerated conversion of the cytosolic
retroviral capsid from particulate to soluble forms. We wished
to examine the effects of restriction-attenuating changes in the
TRIM5 B-box 2 domain on the fate of the retroviral capsid.
FIG. 3. Alteration of two basic residues in the TRIM5rh B-box 2 domain. Cells were transduced with either the empty LPCX vector or a vector
expressing wild-type (wt) TRIM5rh or the following TRIM5rh mutants: K113A/R121A, C97A/H100A, K103A, the mutant with RING deleted
[	(1-93)], the mutant with the RING-B box deleted [	(1-132)], or the mutant with the B-box deleted [	(97-129)]. (A) Cell lysates were analyzed
by Western blotting using antibodies against HA (Anti-HA) and -actin. (B to D) Cf2Th cells expressing the different TRIM5rh variants were
challenged with HIV-1–GFP (B), EIAV-GFP (C), or FIV-GFP (D). GFP-positive cells were counted. Similar results were obtained in three
independent experiments.
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FIG. 4. Effects of altering the charge on residues 113 and 121 of the TRIM5rh B-box 2 domain. Cf2Th cells expressing the indicated wild-type
and mutant TRIM5rh proteins were challenged with HIV-1–GFP (A and D), EIAV-GFP (B), or FIV-GFP (C). GFP-positive cells were counted.
Similar results were obtained in three independent experiments.
10368 DIAZ-GRIFFERO ET AL. J. VIROL.
FIG. 5. Effects of altering residues 111 and 119 of the TRIM5hu B-box 2 domain. Cf2Th cells expressing the indicated wild-type and mutant
TRIM5hu proteins were challenged with N-MLV–GFP (A), B-MLV–GFP (B), EIAV-GFP (C), or FIV-GFP (D). GFP-positive cells were
counted. Similar results were obtained in three independent experiments.
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FIG. 6. Effects of altering the charge on residues 111 and 119 of the TRIM5hu B-box 2 domain. Cf2Th cells expressing the indicated wild-type
and mutant TRIM5hu proteins were challenged with N-MLV–GFP (A and B), EIAV-GFP (C), or FIV-GFP (D). GFP-positive cells were
counted. Similar results were obtained in three independent experiments.
10370 DIAZ-GRIFFERO ET AL. J. VIROL.
First, we examined the fate of the HIV-1 capsid in cells ex-
pressing the wild-type or R121E TRIM5rh protein or in con-
trol cells transduced with the empty LPCX vector. No cytosolic
HIV-1 capsid protein, in either soluble or particulate form, was
detected in the control LPCX-transduced cells incubated with
HIV-1 lacking envelope glycoproteins (Fig. 9A). By contrast,
at 1 hour after infection of these cells with a VSV G glyco-
protein-pseudotyped HIV-1, particulate and soluble capsid pro-
teins were detected in the assay. This result demonstrates that the
assay can distinguish retroviral capsid proteins that have entered
the cytosol through the action of the VSV G glycoprotein from
virions that are nonspecifically attached to or endocytosed into
cells (24, 31). Compared with the results in the control LPCX
cells, a significant decrease in the level of the particulate HIV-1
capsid was observed in the cytosol of TRIM5rh-expressing cells.
By contrast, particulate capsid was detected at this time point in
the cytosol of cells expressing the TRIM5rh R121E mutant.
The fate of the N-MLV capsid in the cytosol of cells express-
ing wild-type TRIM5hu or the R119A and R119E TRIM5hu
mutants was compared with that seen in control cells trans-
duced with the empty LPCX vector. Particulate capsid was
detected in the LPCX-transduced cells and in the cells express-
ing the R119A and R119E TRIM5hu mutants (Fig. 9B). By
contrast, no detectable particulate capsid was observed in cells
expressing wild-type TRIM5hu. Consistent with previous ob-
servations (24, 31), an increase in soluble forms of the N-MLV
capsid was observed in cells expressing the wild-type
TRIM5hu protein compared with the levels of soluble capsid
proteins in the other cells. Thus, although the B-box 2 mutants
are trimeric and retain the ability to bind retroviral capsids,
they are deficient in promoting a decrease in the level of
particulate cytosolic capsid and in restricting infection. Appar-
ently, an “effector” function necessary for the last two pro-
cesses has been compromised by the changes introduced into
the TRIM5 B-box 2 domain.
Effects of B-box 2 changes on TRIM5 degradation. During
the course of these studies, we noticed that the steady-state
levels of some of the B-box 2 mutants of TRIM5rh and
TRIM5hu were increased. Wild-type TRIM5 turns over with
a half-life of approximately 50 to 70 min, and B-box 2 changes
have been shown to affect TRIM5 turnover (3). As steady-
state levels reflect rates of both synthesis and degradation, we
examined whether the B-box 2 mutants exhibited changes in
half-life compared with the wild-type TRIM5 protein. Cf2Th
cells stably expressing the mutant proteins were incubated with
cycloheximide for several hours, during which time the steady-
state levels of the TRIM5 variants were determined by West-
ern blotting. Levels of a control protein, -actin, were mea-
sured in parallel and used as a normalization standard.
Because the proteasome can contribute to the degradation of
FIG. 7. Oligomerization of TRIM5rh and TRIM5hu mutants. 293T cells were transiently transfected with plasmids expressing the indicated
wild-type (wt) or mutant TRIM5 proteins with HA epitope tags. Cells expressing wild-type and mutant TRIM5rh (A) or TRIM5hu (B) proteins
were lysed 48 h after transfection and cross-linked with the indicated concentrations of glycolbis-succinimidylsuccinate. The cell lysates were
subsequently Western blotted with an anti-HA antibody. t, trimer; d, dimer.
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overexpressed TRIM5 (3), we also measured TRIM5 turn-
over in the presence of proteasome inhibitors. Pilot studies
indicated that three different proteasome inhibitors, MG115,
MG132, and clasto-lactacystin, all exerted similar effects on
TRIM5 turnover (data not shown); thus, MG115 was used in
the majority of the experiments.
As expected, the wild-type TRIM5rh and TRIM5hu pro-
teins exhibited half-lives of 48 and 40 min, respectively. These
half-lives were increased only modestly by incubation with the
proteasome inhibitor MG115 (Fig. 10). The measured half-
lives of these proteins were similar regardless of whether the
HA epitope tag used for detection was at the N or C terminus
(or on both termini) (data not shown). Thus, both TRIM5rh
and TRIM5hu proteins are degraded in Cf2Th cells with a
half-life of less than 1 hour by a process that is resistant to
proteasome inhibitors.
The effects of changes in the B-box 2 domain on TRIM5rh
and TRIM5hu half-lives are shown in Fig. 10 and Table 1.
Many of the B-box 2 changes involving arginine 121 of
TRIM5rh and arginine 119 of TRIM5hu resulted in proteins
FIG. 8. Binding of TRIM5rh B-box 2 mutants to assembled HIV-1
capsids. 293T cells were transfected with plasmids expressing the in-
dicated wild-type (wt) and mutant TRIM5rh proteins tagged with HA
epitopes. Thirty-six hours after transfection, the cells were lysed and
the lysates were mixed with HIV-1 CA-NC complexes that had been
assembled in vitro. The mixtures were applied to a 70% sucrose cush-
ion. INPUT represents the mixtures analyzed by Western blotting
before being applied to the 70% cushion. The INPUT mixtures were
Western blotted for the HA tag. The PELLET from the 70% cushion
was analyzed by Western blotting using antibodies against the HA tag
and HIV-1 CA-NC protein.
FIG. 9. Fates of the retroviral capsid in cells expressing TRIM5
variants. (A) Cf2Th cells containing the LPCX empty vector or ex-
pressing wild-type TRIM5rh or the R121E mutant TRIM5rh protein
were incubated with similar amounts of HIV-1–GFP at 4°C for 30 min.
The cells were washed and returned to 37°C, and infection was allowed
to proceed for 16 h. Cell extracts were fractionated on sucrose gradi-
ents, as described in Materials and Methods. Total, soluble and pellet
fractions were analyzed by Western blotting using antibodies against
the HIV-1 p24 capsid protein. (B) Cf2Th cells containing the LPCX
empty vector or expressing the indicated wild-type (wt) and mutant
TRIM5hu proteins were incubated with similar amounts of N-MLV–
GFP at 4°C for 30 min. The cells were washed and returned to 37°C,
and infection was allowed to proceed for 4 h. Cell extracts were
fractionated on sucrose gradients, as described in Materials and Meth-
ods. Total, soluble, and pellet fractions were analyzed by Western
blotting using antibodies against the N-MLV p30 capsid protein.
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with dramatic increases in half-life. Notably, replacement of
these arginine residues with lysine did not increase the stability
of TRIM5rh or TRIM5hu. We conclude that the presence of
a basic residue at position 121 of TRIM5rh or position 119 of
TRIM5hu is important for the rapid turnover of these pro-
teins via a pathway resistant to proteasome inhibitors.
With respect to HIV-1 restriction, the TRIM5rh RING, L1,
and B-box 2 domains can be functionally replaced by those of
human TRIM6 or TRIM34 (14). Because TRIM6 and
TRIM34 exhibit long half-lives compared with TRIM5 (14),
we measured the half-lives of the chimeric proteins [Table 1,
TRIM6-5(CC-B30.2) and TRIM34-5(CC-B30.2)]. Both chi-
meric proteins exhibited very long half-lives compared with
that of wild-type TRIM5rh.
FIG. 10. Turnover of wild-type and mutant TRIM5 proteins. Cf2Th cells stably expressing the indicated TRIM5 proteins were treated with
cycloheximide (CHX) or with cycloheximide and MG115 (CHXMG115). At the indicated times after the initiation of treatment, the cells were lysed.
The cell lysates were Western blotted using an antibody directed against the HA tags on the TRIM5 proteins. The intensities of the bands were estimated
by densitometry and plotted versus time. The results of a typical experiment are shown, with similar results obtained in three separate experiments.
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Modest (approximately twofold) increases in the half-lives of
most of the single-residue B-box 2 TRIM5 mutants were
observed in the presence of proteasome inhibitors (Table 1),
consistent with the observations made of the wild-type
TRIM5rh and TRIM5hu proteins in Cf2Th cells. For a few
mutants, like TRIM5rh R121A and R121D, the effects of
MG115 treatment on the half-life were somewhat greater. A
TRIM5rh protein with a deletion of the RING domain and L1
region [TRIM5rh 	(1-93)] or TRIM5rh proteins with dele-
tions encompassing the B-box 2 domain [TRIM5rh 	(1-132)
and 	(97-129)] exhibited longer half-lives than the wild-type
TRIM5rh protein. These half-lives were increased signifi-
cantly (12- to 45-fold) by MG115 treatment. Thus, some
TRIM5rh mutants, particularly those with deletions encom-
passing the RING and B-box 2 domains, are turned over by
proteasome-mediated pathways.
Effects of changes in arginine 120 in the TRIMCyp B-box 2
domain. The B-box 2 arginine residue (arginine 121 in
TRIM5rh and arginine 119 in TRIM5hu) is also conserved in
the owl monkey restriction factor TRIMCyp as arginine 120.
To examine the contribution of TRIMCyp arginine 120 to
protein turnover and antiretroviral function, this residue was
altered and the phenotypes of the mutants were examined. The
steady-state levels of the TRIMCyp mutants stably expressed
in Cf2Th cells are shown in Fig. 11A. The wild-type TRIMCyp
protein and the TRIMCyp R120K mutant exhibited half-lives
of about 1 hour (Table 1). By contrast, the R120D, R120E, and
R120A mutants of TRIMCyp had half-lives greater than 5 h.
Proteasome inhibition exerted only one- to twofold effects on the
turnover of the wild-type and mutant TRIMCyp proteins. Thus,
like TRIM5, TRIMCyp is rapidly degraded by a process that is
not inhibited by proteasome inhibitors; this process is disrupted
by replacement of the TRIMCyp B-box 2 arginine 120 with amino
acid residues that do not carry a positive charge.
The abilities of the TRIMCyp B-box 2 mutants to restrict
HIV-1 infection were examined by challenging Cf2Th cells
expressing the wild-type and mutant TRIMCyp proteins with
recombinant HIV-1–GFP. The TRIMCyp R120K, R120E,
R120D, and R120A proteins inhibited HIV-1 infection as ef-
ficiently as the wild-type TRIMCyp protein (Fig. 11B). Thus,
the phenotypes of the B-box 2 domain changes differ in the
context of the TRIMCyp and TRIM5 proteins.
Cellular localization of TRIM5 B-box 2 mutants. The in-
tracellular localization of the wild-type TRIM5rh, TRIM5hu,
and TRIMCyp proteins was compared with that of the B-box 2
mutants. The mutants in which arginines 119/120/121 in the
B-box 2 domain were altered to an acidic amino acid residue
demonstrated intense, diffuse staining throughout the cyto-
plasm of the cell (Fig. 12A and B). A similar pattern of staining
was observed for TRIM5rh	(97-129), in which the B-box 2
domain is deleted. The B-box 2 mutants in which arginines
119/120/121 were replaced by lysine or alanine residues exhib-
ited faint, diffuse cytoplasmic staining punctuated by the pres-
ence of scattered cytoplasmic bodies, a pattern similar to that
exhibited by the wild-type TRIM5 proteins.
DISCUSSION
The functions of most TRIM proteins are not known. In a
few cases, TRIM proteins have been shown to recognize a
protein target via their C-terminal domains; the binding of the
TRIM protein results in ubiquitylation and proteasomal deg-
radation of the target protein (10, 17, 33). The mechanism of
retroviral restriction by TRIM5 is currently under investiga-
tion. TRIM5 variants that inhibit HIV-1 infection specifically
recognize HIV-1 capsid complexes assembled in vitro (31). In
the infected cell, TRIM5 promotes the premature conversion
of particulate capsids into soluble capsid proteins (24, 31).
Studies of TRIM5 variants with the RING domain deleted, cells
expressing temperature-sensitive E1 ubiquitin ligase mutants, and
the effects of proteasome inhibitors argue against a model of
capsid ubiquitylation and proteasomal degradation (23, 31).
The work reported here provides insights into the structure-
function relationships of the TRIM5 B-box 2 domain. We
studied a panel of human and rhesus monkey TRIM5 B-box
2 mutants containing alterations of amino acid residues pre-
dicted to be surface exposed (Fig. 1). Most of the mutants
phenotypically resembled the wild-type TRIM5 protein, in-
dicating some degree of structural flexibility on the B-box 2
surface. On the other hand, some mutants were severely
attenuated in the ability to restrict viral infection despite retaining
TABLE 1. Half-lives, retrovirus-restricting activities, and
cytoplasmic staining of TRIM variants
TRIM variant
Half-life (min)a Retrovirus-
restricting
abilityb
Cytoplasmic
stainingcCHX CHX MG115
Wild-type TRIM5rh 48 59  CB
TRIM5rh K113R/R121K 23 29  CB
TRIM5rh R121E 1,541 
10,000  D
TRIM5rh K113A/R121A 764 1,464  CB
TRIM5rh R121A 675 
10,000  CB
TRIM5rh R121D 173 714  D
TRIM5rh C97A/H100A 336 470  CB
TRIM5rh 	(1-93) 150 1,783  D
TRIM5rh 	(97-129) 629 
10,000  D
TRIM5rh 	(1-132) 203 3,072  D
TRIM6-5 (CC-B30.2) 4,933 
10,000  ND
TRIM34-5 (CC-B30.2) 
10,000 
10,000  ND
Wild-type TRIM5hu 40 42  CB
TRIM5hu R119K 29 31  CB
TRIM5hu R119A 231 439  CB
TRIM5hu R119D 361 602  D
TRIM5hu R119E 749 1,518  D
TRIM5hu C95A 253 768  CB
Wild-type TRIMCyp 56 63  CB
TRIMCyp R120K 58 61  CB
TRIMCyp R120D 381 577  D
TRIMCyp R120E 804 1,350  D
TRIMCyp R120A 320 680  CB
a The half-life of the indicated TRIM protein stably expressed in Cf2Th cells
was determined in the presence of cycloheximide (CHX) or cycloheximide and
MG115 (CHXMG115), as described in Materials and Methods. The half-lives
were estimated from semilog plots of TRIM level versus time, in some cases
extrapolating to make the estimate. The values shown are typical of those ob-
tained in at least two experiments. The half-lives of the TRIM6-5(CC-B30.2) and
TRIM34-5(L2-B30.2) proteins were determined in HeLa cells stably expressing
these proteins; the half-life of the wild-type TRIM5rh protein in these cells was
52 min in the presence of CHX and 115 min in the presence of CHX  MG115.
b The retrovirus-restricting ability of each variant was estimated, in compari-
son to the value () observed for the corresponding wild-type protein,
using the data shown in Fig. 2 to 6 and 12. The minus sign indicates no detectable
restricting ability for the appropriate susceptible virus,  indicates activity
comparable to that of the wild-type protein, and  to  indicate interme-
diate levels of potency.
c The intracellular localization of the TRIM variant was determined. The
intracellular localization of the TRIM5rh C97A/H100A, 	(1-93) and 	(1-132)
variants was described in reference 11. The TRIM5rh	(1-93) protein is also
found in the nuclei of expressing cells, where it is associated with nuclear bodies.
CB, cytoplasmic bodies; D, diffuse cytoplasmic staining; ND, not determined.
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the ability to trimerize and to recognize the relevant retroviral
capsid. Thus, these mutants appear to lack an effector function
necessary for retroviral restriction. An overlapping subset of
B-box 2 mutants lost the ability to be rapidly degraded by a
pathway insensitive to proteasome inhibitors. Some changes in
the B-box 2 domain also influenced the subcellular localization
of TRIM5 and TRIMCyp proteins.
A discrete TRIM5 B-box 2 region predicted to reside near
the trimer axis was found to be important for retroviral restric-
tion, formation of cytoplasmic bodies, and protein turnover.
The structural requirements for these three processes differ
subtly but involve arginines 119/120/121 in all three instances.
All primate TRIM5 proteins, as well as owl monkey TRIMCyp,
have arginine residues at these positions (Fig. 13). The rapid
turnover of TRIM5 and TRIMCyp apparently requires a
basic residue at these positions. The structural requirements
for cytoplasmic-body formation and retroviral restriction ap-
pear to be less stringent. Substitution of acidic residues for
arginines 119/120/121 or deletion of the B-box 2 domain results
in a diffuse cytoplasmic staining pattern for TRIM5 and
TRIMCyp, with lack of cytoplasmic-body formation. These
acidic substitutions also attenuate retroviral restriction by
rhesus monkey and human TRIM5 proteins, but not by
TRIMCyp. Replacement of arginine 119 by alanine significantly
impaired the retrovirus-restricting ability of TRIM5hu, al-
though cytoplasmic-body formation and rapid turnover were
not affected. Retroviral restriction by TRIM5rh, on the other
hand, can tolerate the substitution of an alanine residue for
arginine 121. Thus, TRIM5rh R121A forms cytoplasmic bod-
ies and retains potent restricting activity against HIV-1 but,
unlike the wild-type protein, exhibits a long half-life. Likewise,
replacement of the RING and/or B-box 2 domains of
TRIM5rh with those of the long-lived TRIM6, TRIM34, or
TRIM21 proteins also resulted in stable proteins that exhibited
potent antiretroviral activity (Table 1) (3, 14a). Thus, the func-
tions of the TRIM5 B-box 2 domain related to rapid turnover
and retroviral restriction are separable. These results seem
incompatible with recently proposed (1a) models of restriction
in which the TRIM5rh protein and the capsid subunits asso-
ciated with it are degraded through a proteasome-independent
host cell pathway.
The pathway by which TRIM5 and TRIMCyp are rapidly
turned over is not understood. Despite testing multiple pro-
teasome inhibitors, we were unable to eliminate the rapid
turnover of the wild-type TRIM5 and most of the TRIM5
single-amino-acid mutants. Apparently, a nonproteasome pro-
tein degradation pathway interacts with the amino-terminal
TRIM5 domains and results in rapid turnover. The role of
this rapid turnover in the natural function of TRIM5 requires
further investigation.
FIG. 11. Effects of B-box 2 arginine changes on TRIMCyp. (A) The steady-state expression levels of the indicated TRIMCyp variants in Cf2Th cells
were determined by Western blotting with an anti-HA antibody. wt, wild type. (B) Cf2Th cells expressing the indicated TRIMCyp variants were incubated
with HIV-1–GFP. GFP-positive cells were counted. The results of a typical experiment are shown. The experiment was repeated with similar results.
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Our results suggest that the TRIM5 B-box 2 domain con-
tributes to cytoplasmic-body formation but cannot do so when
an acidic residue is present at positions 119/120/121. The for-
mation of cytoplasmic bodies is not sufficient for potent retro-
viral restriction, as evidenced by the weak retroviral restriction
mediated by the TRIM5hu R119A and TRIM5rh K113A/
R121A mutants, both of which are found in cytoplasmic bod-
ies. The necessity of cytoplasmic-body formation for retroviral
restriction by TRIM5 cannot be ruled out by our data, as
acidic substitutions for residue 119 of TRIM5hu or residue
121 of TRIM5rh eliminated both the appearance of cytoplas-
mic bodies and restricting activity. Other studies of TRIM5-
expressing cells in which cytoplasmic bodies have been dis-
rupted or minimized suggest that detectable bodies are not
necessary for efficient inhibition of retrovirus infection (23, 27).
Acidic substitutions involving arginines 119/121 of the
TRIM5 B-box 2 domain, or deletion of this domain, may
coincidentally affect cytoplasmic-body formation and another
property (e.g., association with self or another factor) required
for retroviral restriction.
Disruption of the B-box 2 domain can result in loss of ret-
rovirus-restricting ability for at least two reasons. First, as
shown here, some changes in the TRIM5rh B-box 2 domain
eliminate the ability of the protein to restrict HIV-1 infection
without significantly affecting expression, oligomerization, or
capsid binding. These mutagenic studies suggest that the
TRIM5 B-box 2 domain plays a key role in retroviral restric-
tion separate from the requirements for capsid recognition/
binding. In this study and in previous studies (24, 31), we
observed the accelerated conversion of particulate retroviral
capsids to soluble forms of capsid protein in the cytosol of
infected cells expressing a functional TRIM5 protein com-
pared with that in control cells not expressing TRIM5. No-
tably, this accelerated uncoating of the viral capsid was not
observed in cells expressing the B-box 2 TRIM5 mutants
defective in the “effector function” of retroviral restriction.
Our studies indicate that the majority of the capsid proteins
disassembled during TRIM5-mediated restriction do not un-
dergo ubiquitylation (or other large modification) and are not
degraded. Second, some combinations of changes in several
B-box 2 residues have been shown to decrease the binding of
TRIM5 proteins to the HIV-1 capsid, apparently by affecting
FIG. 12. Subcellular localization of TRIM5rh and TRIM5hu mutants. (A and B) Cf2Th cells stably expressing the indicated wild-type and
mutant TRIM5 or TRIMCyp proteins were fixed and stained using a fluorescein isothiocyanate-conjugated anti-HA antibody as described in
Materials and Methods. Representative confocal microscope images are shown.
10376 DIAZ-GRIFFERO ET AL. J. VIROL.
the relationship of the B-box 2 and B30.2(SPRY) domains
(14b). Understanding these distinct consequences of B-box 2
domain modification will require additional studies.
The B-box 2 arginine residue identified in this work as im-
portant for TRIM5rh and TRIM5hu effector function ap-
pears to be less critical for TRIMCyp-mediated retroviral re-
striction. Deletion or disruption of the B-box 2 domain of
TRIMCyp can lead to a reduction in antiretroviral activity (4).
In general, however, it appears that TRIMCyp anti-HIV-1
activity is less dependent on the integrity of the B-box 2 do-
FIG. 12—Continued.
FIG. 13. Sequence alignment of the B-box 2 domain sequences from different TRIM5 proteins. The B-box 2 domain sequences of the TRIM5
relatives TRIM6, TRIM34, and TRIM22 are also shown for comparison. Residues predicted to coordinate the two zinc ions in the B-box 2 domain
are depicted in red. Residues depicted in black correspond to the consensus sequence for this set of proteins, whereas residues in blue differ from
the consensus sequence. The arginine (119/120/121) studied in this work is conserved in all TRIM5 proteins (black box). In contrast, lysine
(111/113) is conserved only in the TRIM5 proteins of hominoids and Old World monkeys.
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main than is the virus-restricting activity of TRIM5 proteins.
This is consistent with recent observations that moderate levels
of antiretroviral activity can be achieved simply by oligomer-
izing the cyclophilin A domain, a function that does not
require the TRIM5 B-box 2 domain (12a, 36).
The arginine 119/121 residue identified here as being impor-
tant for TRIM5 antiretroviral function, cytoplasmic-body for-
mation, and TRIM5 turnover is predicted to be exposed on
the modeled TRIM5 trimer. This raises the possibility that
the region surrounding arginines 119/121 may be a docking site
for association of TRIM5 with itself or with TRIM5 cofac-
tors that support retroviral restriction or rapid turnover. The
panel of mutants generated in this study should assist the
investigation of these possibilities.
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